AOD-9604 vs HGH (Somatropin)
Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of AOD-9604 and HGH (Somatropin) (also searched as HGH (Somatropin) vs AOD-9604) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
AOD-9604 centers on skin, while HGH (Somatropin) leans toward muscle. On indexed research, HGH (Somatropin) is ahead (AOD-9604: 12 studies, Human evidence; HGH (Somatropin): 82, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •AOD-9604 is strongest for skin; HGH (Somatropin) for muscle.
- •Evidence: AOD-9604 Human evidence (12 studies) vs HGH (Somatropin) Human clinical (82).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Growth Hormone | Growth deficiency treatment
AOD-9604 vs HGH (Somatropin): side-by-side
| Metric | AOD-9604 | HGH (Somatropin) |
|---|---|---|
| Class | Metabolic | Healing |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 12 | 82 |
| Research level | Limited Research | FDA Approved |
| Strongest effect | Skin & aesthetics | Muscle & body comp |
| Healing & recovery | 2.0 | 3.0▲ |
| Muscle & body comp | 1.0 | 4.0▲ |
| Metabolic & appetite | 3.0▲ | 3.0▲ |
| Neuro & mood | 0.0 | 2.0▲ |
| Sleep & circadian | 0.0 | 2.0▲ |
| Inflammation & immune | 1.0 | 2.0▲ |
| Skin & aesthetics | 3.0▲ | 3.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | AOD-9604 | HGH (Somatropin) |
|---|---|---|
| Mechanism | Modified hGH fragment (176–191) | Growth hormone receptor agonist |
| Route | Subcutaneous injection (research use) | Subcutaneous injection |
| Half-life | — | ~20 min |
| Time to peak | — | 3–6 hours |
| Duration of action | — | Variable, up to 24 hours |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is AOD-9604?
A GH-fragment–derived peptide primarily discussed for fat loss and body-composition change, sometimes with cartilage and joint-repair context.
Full AOD-9604 profile, mechanism & studies →What is HGH (Somatropin)?
HGH (somatropin) is recombinant human growth hormone, FDA-approved for pediatric and adult GH deficiency and several wasting and short-stature conditions; widely studied for body composition off-label.
Full HGH (Somatropin) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | HGH (Somatropin) | 3.0/5 effect signal |
| Muscle | HGH (Somatropin) | 4.0/5 effect signal |
| Metabolic | Even | Both ~3.0/5 |
| Neuro | HGH (Somatropin) | 2.0/5 effect signal |
| Sleep | HGH (Somatropin) | 2.0/5 effect signal |
| Inflammation | HGH (Somatropin) | 2.0/5 effect signal |
| Skin | Even | Both ~3.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack AOD-9604 and HGH (Somatropin)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
AOD-9604 vs HGH (Somatropin): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
AOD-9604 has 12 approved studies indexed (Human evidence), and HGH (Somatropin) has 82 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is AOD-9604 or HGH (Somatropin) better?
It depends on your goal. AOD-9604 is strongest for skin; HGH (Somatropin) for muscle. HGH (Somatropin) has more indexed studies (82). See the goal-by-goal breakdown above.
Is AOD-9604 or HGH (Somatropin) better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Is AOD-9604 or HGH (Somatropin) better for muscle?
HGH (Somatropin) leads on the muscle & body-composition axis (4.0/5).
Which has more research, AOD-9604 or HGH (Somatropin)?
AOD-9604 has 12 approved studies indexed (Human evidence); HGH (Somatropin) has 82 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack AOD-9604 and HGH (Somatropin)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of AOD-9604 vs HGH (Somatropin)?
AOD-9604: no community-reported effects logged yet. HGH (Somatropin): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is AOD-9604 or HGH (Somatropin) FDA-approved?
AOD-9604 is a research-use compound and is not FDA-approved. HGH (Somatropin) is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is HGH (Somatropin) better than AOD-9604?
For muscle, HGH (Somatropin) has the edge; for skin, AOD-9604 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.